Microscopic Polyangiitis (MPA)

1. Executive Overview: Understanding Microscopic Polyangiitis (MPA)

Microscopic Polyangiitis (MPA), classified under ICD-10 code M31.7, is a systemic, necrotizing small-vessel vasculitis that predominantly affects the kidneys and lungs. As a member of the Anti-Neutrophil Cytoplasmic Antibody (ANCA)-associated vasculitis (AAV) spectrum, MPA is characterized by a paucity of immune complex deposits in vessel walls, distinguishing it from other forms of vasculitis.

In the realm of nephrology, MPA is a clinical emergency. It typically manifests as a rapidly progressive glomerulonephritis (RPGN), which, if left untreated, leads to irreversible end-stage renal disease (ESRD). The primary hallmark of MPA is the presence of myeloperoxidase (MPO)-ANCA, which triggers an inflammatory cascade resulting in vessel wall necrosis, fibrinoid deposition, and subsequent organ ischemia.

2. Pathophysiology, Etiology, and Risk Factors

The pathogenesis of MPA is rooted in the activation of neutrophils by ANCA. Unlike Granulomatosis with Polyangiitis (GPA), MPA lacks the granulomatous inflammation and typically spares the upper respiratory tract.

The Mechanism of Injury

1. ANCA Activation: Circulating MPO-ANCA antibodies bind to antigens on the surface of primed neutrophils.
2. Degranulation: This binding triggers a respiratory burst and the release of pro-inflammatory cytokines and reactive oxygen species.
3. Endothelial Damage: Activated neutrophils adhere to the vascular endothelium, causing necrotizing inflammation, particularly in the glomerular capillaries.
4. Glomerular vs. Tubular Pathology: While the primary injury is glomerular (leading to crescent formation), the resulting ischemia and inflammation often lead to secondary tubular atrophy and interstitial fibrosis if the glomerular basement membrane (GBM) is breached.

Risk Factors and Etiology

While the exact trigger remains idiopathic, genetic predispositions (specifically HLA-DRB1 alleles) and environmental exposures (silica dust, certain medications like propylthiouracil or hydralazine) are recognized as potential triggers for the autoimmune response.

3. Signs, Symptoms, and Clinical Presentation

MPA is a systemic disease. While the kidneys are the most frequently involved organ, the clinical presentation is often multisystemic.

Renal Manifestations

• Nephritic Syndrome: Hematuria (often with dysmorphic RBCs or red cell casts), proteinuria (usually sub-nephrotic, but can be nephrotic range), and hypertension.
• Rapidly Progressive Glomerulonephritis (RPGN): A swift decline in eGFR over days or weeks.
• Uremia: Symptoms of renal failure, including fatigue, nausea, pruritus, and fluid overload.

Extra-Renal Manifestations

• Pulmonary: Pulmonary capillaritis leading to diffuse alveolar hemorrhage (DAH), presenting as hemoptysis, dyspnea, and pulmonary infiltrates.
• Constitutional: Fever, significant weight loss, and severe malaise.
• Dermatological: Palpable purpura or livedo reticularis.
• Neurological: Mononeuritis multiplex (peripheral nerve involvement).

4. Diagnostic Evaluation and Workup

A timely diagnosis is imperative to salvage renal function. The diagnostic pathway follows a structured approach.

Laboratory Assays

1. ANCA Serology: MPO-ANCA is positive in approximately 70-80% of MPA cases.
2. Renal Function Tests: Serial monitoring of Serum Creatinine and eGFR is critical to assess the velocity of decline.
3. Urinalysis: Microscopic examination for hematuria and red blood cell casts is the gold standard for identifying active glomerular inflammation.
4. Inflammatory Markers: Elevated ESR and CRP are non-specific but common.

Renal Biopsy: The Gold Standard

A renal biopsy is mandatory to confirm the diagnosis and stage the disease.
* Indications: Unexplained hematuria with rising creatinine or acute nephritic syndrome.
* Histological Findings: Focal segmental necrotizing glomerulonephritis with crescent formation. Immunofluorescence (IF) typically shows "pauci-immune" patterns, meaning a lack of significant immunoglobulin or complement deposition.

Imaging

• Chest X-ray/CT: Essential for detecting pulmonary capillaritis or alveolar hemorrhage.
• Renal Ultrasound: Used to rule out obstructive uropathy and assess for chronic changes (e.g., cortical thinning, increased echogenicity).

5. Therapeutic Interventions and KDIGO Pathways

Treatment is divided into the Induction Phase (to achieve remission) and the Maintenance Phase (to prevent relapse).

Induction Therapy

According to KDIGO guidelines, the standard of care for severe MPA includes:
* Glucocorticoids: High-dose pulse methylprednisolone, followed by a tapering oral prednisone regimen.
* Cyclophosphamide or Rituximab: Rituximab has become the preferred agent for many, showing non-inferiority to cyclophosphamide with fewer long-term side effects.
* Plasma Exchange (PLEX): Reserved for patients with severe pulmonary hemorrhage or those with very high serum creatinine levels (e.g., >5.7 mg/dL) who may benefit from the rapid removal of circulating ANCA.

Maintenance Therapy

• Goal: Sustained remission.
• Agents: Rituximab (scheduled infusions), Azathioprine, or Mycophenolate Mofetil.

Management of Complications

• CKD-MBD: As MPA progresses to CKD, patients require management of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) through phosphate binders, Vitamin D analogs, and calcium monitoring.
• Uremia: If ESRD is reached, Renal Replacement Therapy (RRT) via hemodialysis or peritoneal dialysis is indicated.

6. Frequently Asked Questions (FAQ)

1. Is Microscopic Polyangiitis curable?
MPA is considered a chronic condition. While we can achieve "remission," the disease has a risk of relapse, requiring lifelong monitoring by a nephrologist.

2. What is the difference between GPA and MPA?
GPA involves granulomas and typically affects the upper respiratory tract (sinuses/nose). MPA is strictly a small-vessel vasculitis that lacks granulomas and rarely involves the upper airway.

3. How often should I check my kidney function?
In the acute phase, creatinine and eGFR may be checked daily or weekly. In remission, monitoring occurs every 3 to 6 months.

4. Can MPA cause permanent kidney damage?
Yes, if the glomerular damage is too extensive (crescents occupy >50% of glomeruli), it can lead to permanent scarring (fibrosis) and ESRD.

5. What is the role of Rituximab in MPA?
Rituximab depletes CD20+ B-cells, effectively stopping the production of new ANCA antibodies, making it a cornerstone of modern therapy.

6. Is a renal biopsy painful?
A biopsy is performed under local anesthesia with ultrasound guidance. While there is minor discomfort and a risk of bleeding, it is the most vital diagnostic tool for your care.

7. Does MPA affect the lungs?
Yes, MPA can cause pulmonary capillaritis, which may lead to life-threatening bleeding into the lungs (alveolar hemorrhage).

8. Will I need dialysis?
Only if the kidneys sustain severe, irreversible damage. Early intervention significantly reduces the likelihood of requiring long-term dialysis.

9. What are the warning signs of a relapse?
Return of hematuria, unexplained fatigue, skin rashes (purpura), or worsening joint pain should be reported to your doctor immediately.

10. Are there specific diets for MPA patients?
A kidney-friendly diet (low-sodium, controlled protein) is often recommended, especially if your eGFR is declining, to reduce the burden on your kidneys.

Disclaimer: This guide is for educational purposes and does not replace professional medical advice. Always consult with your nephrologist regarding your specific clinical markers and treatment plan.